Cargando…
A decade of clinical development of PARP inhibitors in perspective
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a f...
Autores principales: | Mateo, J, Lord, C J, Serra, V, Tutt, A, Balmaña, J, Castroviejo-Bermejo, M, Cruz, C, Oaknin, A, Kaye, S B, de Bono, J S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771225/ https://www.ncbi.nlm.nih.gov/pubmed/31218365 http://dx.doi.org/10.1093/annonc/mdz192 |
Ejemplares similares
-
PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015) -
Opinion: PARP inhibitors in cancer—what do we still need to know?
por: Wicks, Andrew J., et al.
Publicado: (2022) -
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
por: Cruz, C, et al.
Publicado: (2018) -
PARP inhibitors: the race is on
por: Brown, Jessica S, et al.
Publicado: (2016) -
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant
por: Pettitt, Stephen J., et al.
Publicado: (2023)